US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

23.98

-0.4500-1.84%

Post-market: 20.00-3.9800-16.60%19:06 EDT

Volume:219.07K

Turnover:4.74M

Market Cap:269.09M

PE:-3.06

High:24.00

Open:23.63

Low:19.57

Close:24.43

Loading ...

Overview Company News Filings

Palvella Therapeutics initiated with an Outperform at Scotiabank

Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity

Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

Palvella Therapeutics to Expand Phase 3 Selva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

THOMSON REUTERS

TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target

MT Newswires Live

Palvella Therapeutics Initiated at Buy by TD Cowen

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

BRIEF-Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies

Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Microcystic Lms With Data Expected Q1 2026

THOMSON REUTERS

Palvella Therapeutics Announces Publication of Results From Phase 2 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

THOMSON REUTERS

Palvella Therapeutics Inc - Qtorin Rapamycin Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS

Palvella Therapeutics Inc - 100% Participants Show Improvement After 12 Weeks of Qtorin Rapamycin

THOMSON REUTERS

Palvella Doses 1st Patients in Phase 2 Study of Venous Malformation Treatment Drug

MT Newswires Live

BRIEF-Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin

Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial

Palvella Therapeutics Announces First Patients Dosed in Phase 2 Toiva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Cutaneous Venous Malformations

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":23.98,"timestamp":1743796800000,"preClose":24.43,"halted":0,"volume":219066,"hourTrading":{"tag":"盘后","latestPrice":20,"preClose":23.98,"latestTime":"19:06 EDT","volume":207,"amount":4174.96,"timestamp":1743807996614},"delay":0,"floatShares":6497315,"shares":11221307,"eps":-7.832217,"marketStatus":"Market Closed","change":-0.45,"latestTime":"04-04 16:00:00 EDT","open":23.63,"high":24,"low":19.57,"amount":4739853.492636,"amplitude":0.181334,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.832217,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":24.43,"preHourTrading":{"tag":"盘前","latestPrice":23.4,"preClose":24.43,"latestTime":"09:28 EDT","volume":28,"amount":699.529964,"timestamp":1743773280163},"postHourTrading":{"tag":"盘后","latestPrice":20,"preClose":23.98,"latestTime":"19:06 EDT","volume":207,"amount":4174.96,"timestamp":1743807996614},"volumeRatio":2.749591,"impliedVol":0.4864,"impliedVolPercentile":0.5532},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6497315,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":2.749591,"shares":11221307,"dividePrice":0,"high":24,"amplitude":0.181334,"preClose":24.43,"low":19.57,"week52Low":6.2,"pbRate":"4.30","week52High":29.27,"institutionHeld":0,"latestPrice":23.98,"eps":-7.832217,"divideRate":0,"volume":219066,"delay":0,"ttmEps":-7.832217,"open":23.63,"prevYearClose":12,"prevWeekClose":28.1,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":28.1,"twentyDayClose":24.55,"sixtyDayClose":14.73},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517818664","title":"Palvella Therapeutics initiated with an Outperform at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517818664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517818664?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:55","pubTimestamp":1741348542,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $50 price target. The firm says Pal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2514866341","title":"Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866341?lang=en_us&edition=fundamental","pubTime":"2025-02-27 01:56","pubTimestamp":1740592560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 12:56 ET (17:56 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2514483030","title":"Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2514483030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514483030?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:17","pubTimestamp":1740575855,"startTime":"0","endTime":"0","summary":"Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Palvella Therapeutics (PVLA – Research Report). The associated price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-palvella-therapeutics-driven-by-promising-qtorin-rapamycin-trials-and-strategic-expertise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-palvella-therapeutics-driven-by-promising-qtorin-rapamycin-trials-and-strategic-expertise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2514874099","title":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb. 25, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45thAnnual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET.QTORIN rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-present-td-cowen-130000584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","COWN","PVLA","HCSG","BK4207","BK4585","TD","BK4137","BK4127","BK4566"],"gpt_icon":0},{"id":"2513072295","title":"Palantir initiated, Roku upgraded: Wall Street’s top analyst calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2513072295","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513072295?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:35","pubTimestamp":1740148520,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Discover the Best Stocks and Maximize Your Portfolio:. See what stocks are receiving strong buy ratings from top-rated analysts.Filter, analyze, and streamline your search for investment opportunities with  TipRanks’ Stock Screener.Jefferies upgraded Roku  to Hold from Underperform with a price target of $100, up from $55, following the Q4 outperformance. Roku’s 25% year-over-year Platform growth was well ahead of its guidance as the company executes on third party integrations and improving fill rates, the firm tells investors in a research note.Morgan Stanley upgraded SolarEdge  to Equal Weight from Underweight with a price target of $18, up from $11. The company’s stronger free cash flow generation and clearer strategic direction reduces liquidity concerns, the firm tells investors in a research note.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/palantir-initiated-roku-upgraded-wall-143520208.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palantir-initiated-roku-upgraded-wall-143520208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LRCX","SNOW","ROKU","CE","SEDG","BBNX","BAX","NXPI","ZSPC","GRAB","PLTR","DTE","PVLA","GRABW","CMS","AXON"],"gpt_icon":1},{"id":"2510388389","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510388389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510388389?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:18","pubTimestamp":1739276280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2025 07:18 ET (12:18 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2510854433","title":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854433?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:10","pubTimestamp":1739193002,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin Rapamycin) Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:PALVELLA THERAPEUTICS TO EX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA1D6KNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2510040851","title":"Palvella Therapeutics to Expand Phase 3 Selva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old","url":"https://stock-news.laohu8.com/highlight/detail?id=2510040851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510040851?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA1D6KNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2509283209","title":"TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2509283209","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509283209?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:49","pubTimestamp":1738759788,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COWN","PVLA","TD"],"gpt_icon":0},{"id":"2509640706","title":"Palvella Therapeutics Initiated at Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2509640706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509640706?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:17","pubTimestamp":1738757820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 07:17 ET (12:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TD","BK4566","BK4585","BK4207","PVLA","BK4127","COWN"],"gpt_icon":0},{"id":"2502886303","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2502886303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502886303?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:16","pubTimestamp":1736514960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 08:16 ET (13:16 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2502086369","title":"BRIEF-Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502086369","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502086369?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:11","pubTimestamp":1736514707,"startTime":"0","endTime":"0","summary":"Jan 10  - Palvella Therapeutics Inc   :   * PALVELLA THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 2 CLINICAL TRIAL OF QTORIN 3.9% RAPAMYCIN ANHYDROUS GEL  FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS IN THE JOURNAL OF VASCULAR ANOMALIES   * PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR MICROCYSTIC LMS WITH DATA EXPECTED Q1 2026   * PALVELLA THERAPEUTICS INC - QTORIN RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS   * PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW IMPROVEMENT AFTER 12 WEEKS OF QTORIN RAPAMYCINSource text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2502868233","title":"Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Microcystic Lms With Data Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868233?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2502463868","title":"Palvella Therapeutics Announces Publication of Results From Phase 2 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502463868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502463868?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502402868","title":"Palvella Therapeutics Inc - Qtorin Rapamycin Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2502402868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502402868?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2502086823","title":"Palvella Therapeutics Inc - 100% Participants Show Improvement After 12 Weeks of Qtorin Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2502086823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502086823?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA8JP7B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2502777700","title":"Palvella Doses 1st Patients in Phase 2 Study of Venous Malformation Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2502777700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502777700?lang=en_us&edition=fundamental","pubTime":"2025-01-09 00:42","pubTimestamp":1736354574,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.Venous malf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2501720578","title":"BRIEF-Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin","url":"https://stock-news.laohu8.com/highlight/detail?id=2501720578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501720578?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:00","pubTimestamp":1736344837,"startTime":"0","endTime":"0","summary":"Jan 8 (Reuters) - Palvella Therapeutics Inc   :   * PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN RAPAMYCIN) FOR T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2501724266","title":"Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501724266?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:15","pubTimestamp":1736342141,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced the first patients have recently been dosed in TOIVA, a multicenter, Phase 2 clinical trial designed to eval...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2501972154","title":"Palvella Therapeutics Announces First Patients Dosed in Phase 2 Toiva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Cutaneous Venous Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2501972154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501972154?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA68MDGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1742961600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-03","current":-17.359106,"percent":0,"low":-17.359106,"twenty":20.674177,"median":26.844623,"eighty":43.418951,"high":46.119317,"avg":28.666569,"sd":12.273722,"marketCap":302638649},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-03","current":-17.359106,"twenty":20.674177,"median":26.844623,"eighty":43.418951,"marketCap":302638649}],"updateTime":1743832448562}}}